Business
TherapeuticsMD Announces Poster Presentation of ANNOVERA® Data at the American College of Obstetricians and Gynecologists 2021 Annual Meeting
-Poster included analyses of ANNOVERA Phase 3 menstrual bleeding profile data- BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an
About this update from Therapeuticsmd, Inc.
[{"type":"text","content":"\n-Poster included analyses of ANNOVERA Phase 3 menstrual bleeding profile data-\n\n BOCA RATON, Fla.--(BUSINESS WIRE)--\nTherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced Phase 3 menstrual bleeding profile data for ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system) was presented at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting conducted virtually from April 30 to May 2, 2021.\n\n“Menstrual bleeding patterns for women may change with contraceptive use, and predictable bleeding (cycle control) is a key factor that impacts women’s selection, adherence and continuation of combined hormonal contraception. In clinical studies, ANNOVERA showed predictable scheduled bleeding for most women. An unpredictable bleeding profile is very important because it is a common reason that women tend to switch among different contraceptives,” said David F. Archer, MD at Eastern Virginia Medical School.\n\nResults were pooled from two identically designed, open-label Phase 3 trials of ANNOVERA. Bleeding data were available from 2,070 women a total of 453,622 patient-days evaluated for bleeding. Based on ANNOVERA use for up to 13 cycles, a daily average of 94.8% to 97.6% of women reported no unscheduled bleeding in each cycle. The daily percentage of women presenting unscheduled bleeding (≤1.4%) or spotting (≤3.6%) was consistently low throughout the 13 cycles of ANNOVERA use. The median number of unscheduled bleeding/spotting days remained stable across the 13 cycles of ANNOVERA use. Less than 2% of women discontinued ANNOVERA due to bleeding-related adverse events.\n\nAbout ANNOVERA\n\nANNOVERA is the first and only FDA-approved long-lasting, reversible contraceptive for women of reproductive age that is patient-controlled and procedure-free. ANNOVERA was developed by the global non-profit research organization, Population Council, and has been licensed to TherapeuticsMD for the U.S. market.\n\nIMPORTANT RISK INFORMATION\n\n\nDo not use ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system) if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious heart and blood vessel (cardiovascular) side effects from hormonal birth control methods, including death from heart attack, blood clots, o...